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ABSTRACT 
RATIONALE: Evaluation of a pleural effusion has historically focussed on establishing a single 
aetiology. Pleural fluid may accumulate through multiple pathophysiological processes. The 
prevalence of multiple aetiology in pleural effusions has not been established. The 
identification of contributing processes may improve clinical outcomes. 
OBJECTIVE: The objective of this prospectively collected case series was to establish the 
prevalence and nature of multiple aetiology in unilateral pleural effusions. 
METHODS: Consecutive patients presenting with an undiagnosed unilateral pleural effusion 
were recruited at a tertiary pleural centre. Patients underwent a comprehensive structured 
clinical work up and were followed up for a minimum of 12 months after which one or more 
diagnoses was recorded independently by two experienced clinicians. 
MEASUREMENTS AND MAIN RESULTS: 130 patients were recruited to the study over a 24 
month period and 126 patients completed follow up. 88 patients (70%) had a single cause 
for their pleural effusion and 38 (30%) had multiple causes. Serum NT-pro BNP ≥ 1500 pg/ml 
was predictive of multiple aetiology, the most common cause of which was congestive heart 
failure. NT-pro BNP had a sensitivity and specificity of 79% and 88% respectively for 
establishing heart failure as a primary or contributory cause. 13 patients with a malignant 
pleural effusion had an NT-pro BNP ≥ 1500 pg/ml. 
CONCLUSIONS: This study is the first to establish the prevalence of multiple aetiology in 
patients with unilateral pleural effusions. 38 patients (30%) had multiple causes for their 
effusion. The identification of multiple pathology may be important in determining optimum 
treatment and improving patients’ symptoms. 
TRIAL REGISTRATION: Central Bristol research ethics committee (Reference: 08/H0102/11) 
Introduction 1 
Historically, the diagnostic evaluation of pleural effusions has been structured around 2 
identifying a single aetiology. The binary classification system of Light’s criteria divides 3 
effusions into transudates and exudates and presupposes a single disease process leading to 4 
fluid accumulation (1). A number of potential mechanisms which may lead to accumulation 5 
of pleural fluid in disease are described: increased permeability of the pleural membrane, 6 
increased pulmonary microvascular pressure, decreased intrapleural pressure, decreased 7 
plasma oncotic pressure and an obstruction or reduction in lymphatic flow (2). Given these 8 
different mechanisms, it may follow that the accumulation of pleural fluid, to a degree 9 
which causes symptoms, may well be a multifactorial process. The fact that Light’s criteria 10 
(1) has been shown to be neither completely sensitive (3, 4) nor specific for heart failure and 11 
that malignant pleural effusions may be misclassified as transudates (5) may be explained, in 12 
some instances, by multiple aetiologies driving fluid accumulation. This may present 13 
opportunities for tailored treatment in patients with contributing pathological processes. 14 
The presence of five different disease processes giving rise to a pleural effusion 15 
sequentially in a single patient has been described (6). Although an extreme example, this 16 
case report illustrates the importance of considering alternative mechanisms of fluid 17 
accumulation both over time and simultaneously, and how this may affect formulation of an 18 
optimal management strategy. 19 
No previous prospectively study has set out to define the prevalence of multiple 20 
pathologies contributing to pleural effusions. This study recruited consecutive patients 21 
presenting with undiagnosed unilateral pleural effusions to a single centre with the aim of 22 
establishing this.  23 
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The utility of N-Terminal pro Brain natriuretic peptide (NT-pro BNP) has been assessed 24 
in patients with pleural effusions (7-9), though this has typically been in patients with a high 25 
pre-test probability of heart failure or bilateral effusions (8, 10-12). We have therefore 26 
evaluated NT-pro BNP in a group of patients with undiagnosed unilateral pleural effusions 27 
and established its role in predicting multiple aetiology. As serum and pleural fluid NT-pro 28 
BNP levels are closely correlated, serum NT-pro BNP alone was measured (11). 29 
We hypothesised that, in patients presenting with a symptomatic unilateral pleural 30 
effusion, a robust and structured follow-up will establish the prevalence of multiple 31 
aetiology. The study also aimed to establish any factors predicting the presence of multiple 32 
aetiology. 33 
Methods 34 
Study Design and Patients 35 
This study prospectively recruited consecutive patients presenting to North Bristol NHS 36 
Trust (UK) with a new undiagnosed unilateral pleural effusion. Recruitment began in April 37 
2008 and the final patient completed follow up in March 2013. Patients were followed up 38 
for a minimum of 12 months, though some patients required longer follow-up with interval 39 
imaging for two years or more before a diagnosis was definitively reached. The study was 40 
approved by the Central Bristol research ethics committee (Reference 08/H0102/11), and all 41 
participants gave written informed consent for study participation. 42 
Procedures 43 
All patients underwent a comprehensive clinical assessment including a full medical history 44 
and clinical examination with prospective data collection. World health organisation 45 
performance status was recorded. Pleural effusions were classified by laterality and size 46 
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based on the chest x-ray at the time of presentation: [small (≤1/3 hemithorax), moderate (> 47 
1/3 and ≤ 1/2 hemithorax) and large (> 1/2 hemithorax)]. Diagnostic thoracentesis was 48 
undertaken with ultrasound guidance in all patients. Blood tests were performed including a 49 
full blood count, urea and electrolytes, liver function tests, C reactive protein, total protein, 50 
lactate dehydrogenase and an NT-pro BNP. Pleural fluid analysis included a total protein, 51 
lactate dehydrogenase, glucose, microscopy and culture and cytological analysis with a 52 
differential cell count. Chest radiographs, computed tomography, electrocardiograms and 53 
echocardiograms were also carried out. NT-pro BNP levels were measured using a point of 54 
care sandwich enzyme-linked immunosorbent assay test kit (Cobas h232 – Roche 55 
Diagnostics, Germany) according to the manufacturer’s instructions. The test has intra-assay 56 
variation of <8% and measured range of 60-3000 pg/ml. The cut off (1500 pg/ml) was used 57 
as has been recommended in earlier studies (9). 58 
Computed tomography (CT) scan reports were categorised on the likelihood of 59 
malignant disease as: benign/inflammatory, suspicious for malignancy, probable malignancy 60 
or definite malignancy. Pleural biopsies were performed when clinically necessary, either 61 
when the diagnosis was not clear, or if malignancy was suspected. 62 
After a minimum of 12 months had elapsed from time of recruitment, a comprehensive 63 
case note review was undertaken with review of available results by two independent 64 
experienced consultant chest physicians (NAM, JEH). All clinical details were available, with 65 
the exception of serum NT-pro BNP levels, to which reviewing consultants were blinded. 66 
One primary diagnosis and up to two contributory diagnoses were recorded. Required 67 
clinical criteria for specific diagnoses are listed in Appendix 1. In case of disagreement a 68 
consensus was established through both consultants reappraising relevant investigations 69 
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and clinical details. Where multiple diagnoses were thought to have contributed to the 70 
effusion, these were ranked as primary and secondary causes by their degree of 71 
contribution to the effusion based on clinical details, pleural fluid analysis and their 72 
temporal relationship with the effusion. In cases of uncertainty the cause thought to have 73 
led to the patient’s initial presentation was assigned the primary cause. A consensus 74 
decision was made when necessary. 75 
Statistical analysis 76 
Non-normally distributed data were expressed as medians with interquartile ranges. 77 
Frequency data were expressed as number of patients with percentage of total in 78 
parentheses. The sensitivity, specificity, positive predictive value (PPV) and negative 79 
predictive values (NPV) were calculated for Light’s criteria in identifying an exudative cause 80 
for the pleural effusion and for NT-pro BNP in establishing a primary diagnosis of congestive 81 
heart failure (CHF) and a contribution of CHF to the effusion. All pleural effusions other than 82 
those due to CHF, hepatic hydrothorax or renal failure were considered to have an 83 
exudative cause. 84 
Chi-squared test was used to compare the occurrence of multiple aetiologies between 85 
transudates and exudates, between different primary aetiologies and between lung cancer 86 
and mesothelioma. Chi-squared test was also used to examine the relationship between the 87 
side of effusion, its aetiology and categorisation by Light’s criteria. NT-pro BNP levels were 88 
compared between groups of patients with a single or multiple cause for their effusion using 89 
the Mann-Whitney test. The association of NT-pro BNP level with single or multiple 90 
aetiology was tested for the whole group and for all patients excluding those with a primary 91 
diagnosis of CHF. Statistical analysis was performed with Stata 13.1. 92 
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Results 93 
176 patients were screened for study entry. Figure 1 illustrates the reasons potential 94 
participants were excluded. 130 patients were recruited to the study, 4 patients were lost to 95 
follow up and 126 patients were followed up for 12 months or until death and included in 96 
the final analysis. Patient characteristics and the primary diagnosis are shown in Table 1. The 97 
classification of patients’ pleural effusions by Light’s criteria, the predominant cell type and 98 
CT features are summarised in Table 2. The primary diagnosis of the cause for the pleural 99 
effusion was consistent between reporting consultants (kappa=0.95). 100 
Multiple aetiology 101 
88 patients (70%) had one identified cause for their pleural effusion, 35 patients (28%) had 102 
two causes and 3 patients (2%) had three causes. In the 38 patients with more than one 103 
cause there were 41 secondary or tertiary causes of which the most common was CHF 104 
(n=21, 51%), followed by pleural infection (n=8, 20%) and pleural malignancy (n=7, 17%). 105 
Other contributing causes, including benign asbestos pleural effusion (BAPE) (n=3), 106 
pulmonary embolism (PE) (n=1) and renal failure (n=1), accounted for the remainder. 107 
Figure 2 demonstrates the number of patients in each primary diagnostic category with 108 
a multiple cause for their effusion and whether that was due to CHF or another secondary 109 
cause. Notable patterns were CHF as a contributory cause in patients with malignant pleural 110 
disease (8/58 – 14%), CHF as a contributory cause in patients with both BAPE (3/11, 27%) 111 
and idiopathic pleuritis (2/8, 25%) and the prevalence of both malignancy (2/11, 18%) and 112 
CHF (2/11, 18%) in patients with a primary diagnosis of pleural infection. 113 
Malignancy 114 
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Of 58 patients with a primary diagnosis of malignancy, the most common sites were lung 115 
and mesothelioma as shown in Table 3. Rates of cytological diagnoses were lower in 116 
patients with mesothelioma than with other causes of pleural malignancy (11% vs 38%; 117 
p=0.04). Multiple aetiology was significantly more common in patients with lung cancer 118 
compared with those with mesothelioma (41% vs 6%; p=0.01). 119 
Laterality 120 
Patients with a primary diagnosis of heart failure had a right sided effusion in 76% of cases 121 
(16/21) compared with 59% (62/105) in those patients with an alternative primary 122 
diagnosis. The apparent tendency of patients with heart failure to be more likely to have a 123 
right sided effusion was not statistically significant (p=0.14). No relationship was detected 124 
between the side of pleural effusion and the effusion being classified as a transudate by 125 
Light’s criteria (p=0.24) or there being multiple causes of the pleural effusion (p=0.54). 126 
Light’s Criteria 127 
Light’s Criteria had a sensitivity of 97.9%, specificity 73.9%, PPV 94.1% and NPV 89.5% for 128 
the correct identification of an exudative cause for the pleural effusion. The distribution of 129 
transudates and exudates amongst diagnostic groups is shown in Figure 3. The category 130 
‘Other’ includes patients with a PE, an effusion following coronary artery bypass grafting, 131 
transudative effusions due to hepatic hydrothorax or renal impairment and effusions due to 132 
connective tissue disease or medication. Light’s criteria was unavailable in six patients due 133 
to missing pleural fluid or serum levels, including two patients with purulent fluid pleural 134 
fluid for whom levels were not measurable. Six patients with a primary diagnosis of CHF 135 
were erroneously classified as an exudate by Light’s criteria. Two patients were misclassified 136 
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as a transudate by Light’s criteria, one had a benign asbestos pleural effusion and the other 137 
a pulmonary embolism, both of these patients had an elevated NT-pro BNP. 138 
NT-pro BNP Results 139 
In order to establish the value of NT-pro BNP, physicians assigning diagnoses were blinded 140 
to NT-pro BNP results. Using a threshold of 1500 pg/ml, NT-pro BNP measurement had a 141 
sensitivity of 76.2%, a specificity of 74.3%, a PPV of 37.2% and an NPV of 94.0% in 142 
establishing a primary diagnosis of CHF. In terms of establishing CHF as a primary or a 143 
contributory cause the sensitivity was 78.6%, specificity 88.1%, PPV 76.7% and NPV 89.2%. 144 
13 patients with an NT-pro BNP ≥1500 had a malignant pleural effusion, and therefore it is 145 
clear that an elevated NT-pro BNP cannot reliably be used to exclude a malignant aetiology 146 
for a pleural effusion.  147 
CT Features 148 
A CT demonstrating definite malignant features had a 44.6% sensitivity and 100% specificity 149 
for the identification of patients with pleural malignancy (PPV 100%, NPV 59.6%). A CT 150 
demonstrating probable or definite malignant features had a sensitivity of 64.6% and 151 
specificity 92.5% (PPV 91.3%, NPV 68.1%). 152 
Predicting multiple aetiology 153 
NT-pro BNP levels were higher in patients with multiple aetiology (Median 1964 pg/ml, IQR 154 
935-3000) than in those with a single cause for their pleural effusion (263, 88-1057; 155 
p<0.001). This finding remained significant (p<0.001) when patients with a primary diagnosis 156 
of CHF were excluded. However, the prediction of a multiple aetiology with NT-pro BNP 157 
related to the identification of those patients with CHF as a secondary or tertiary cause of 158 
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their pleural effusion. The proportion of patients with transudates and exudates by Lights’ 159 
criteria was not significantly different in patients with single (13% transudates) or multiple 160 
aetiology (23% transudates; p=0.176). 161 
 162 
Discussion 163 
This prospective study of 126 patients with unilateral effusions is the first to establish the 164 
prevalence of multiple aetiology. In patients undergoing robust follow up, multiple 165 
aetiologies were present in 30% of patients. NT-pro BNP levels were significantly higher in 166 
the group of patients with multiple causes for their pleural effusion, compared with those 167 
patients with a single cause. 168 
Some disease processes may, in isolation, not give rise to a symptomatic effusion but 169 
when they co-exist with a second process, might result in a significant effusion. The 170 
presence of other contributing processes may help explain the variable presence of pleural 171 
effusion in conditions such as mesothelioma or benign asbestos pleural disease and the 172 
unpredictable speed of accumulation of a pleural effusion in patients with the same 173 
condition. 174 
Our data has demonstrated Light’s criteria to have an impressive sensitivity (98%) and 175 
PPV (94%) for the identification of an exudative cause for the pleural effusion. Only two 176 
patients were misclassified as transudates by Light’s criteria, one patient with a PE and 177 
another with a benign asbestos pleural effusion. Light’s criteria was less effective in the 178 
identification of a transudative cause for the effusion, with six patients out of 21 (29%) with 179 
CHF classified in error as an exudate. This misclassification rate is similar to that described 180 
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previously (4). Of patients with CHF, only two of the six patients with exudates were on 181 
diuretic treatment at the time of thoracentesis compared with 8 out of 14 patients with 182 
transudates, suggesting that in our study, diuretic therapy was not an important predictor of 183 
elevated pleural fluid protein levels as has been previously suggested (13). The albumin 184 
gradient has been shown to be potentially more specific than Light’s criteria in patients 185 
receiving diuretic therapy (14). Unfortunately albumin gradient was not calculable within 186 
this study, as though serum albumin levels were available, pleural fluid albumin levels were 187 
not. 188 
Of the 58 patients with a diagnosis of malignancy 12 (21%) had a multiple aetiology 189 
contributing to their pleural effusion. Lung cancer patients were significantly more likely to 190 
have a multiple aetiology compared with patients with mesothelioma. The reasons for this 191 
are unclear, but the difference may reflect a difference in rates of pre-existing comorbidity. 192 
Alternatively, this could be hypothesised to be due to differences in the process of fluid 193 
accumulation between patients with lung cancer and metastatic disease to the pleura and 194 
those with mesothelioma. 195 
CT features appeared to have poor sensitivity for the diagnosis of pleural malignancy 196 
within our study population. Five patients with pleural malignancy (7.7%) had CT features 197 
classified as indicating benign disease only, and a further 18 patients (27.7%) with pleural 198 
malignancy had a CT with some suspicious features, but were not classified as probable or 199 
definite malignancy. This finding should highlight the caution required in using radiology in 200 
isolation for diagnosis, and the need for interval imaging and close clinical follow-up in cases 201 
where there is doubt regarding the diagnosis. CT findings were, by contrast, a specific 202 
marker of malignancy. Three patients with BAPE and one patient with idiopathic pleuritis 203 
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had CT findings classified as indicative of probable malignant disease but all patients with 204 
definite features of malignancy on CT were ultimately diagnosed with pleural malignancy. 205 
This study is the first to prospectively evaluate the utility of NT-pro BNP in undiagnosed 206 
unilateral pleural effusions. In a meta-analysis of 10 previous studies, pleural fluid NT-pro 207 
BNP is reported to have a sensitivity of 94% and specificity of 94% (15). In some clinical 208 
settings, such as critical care, caution is advised in view of false positive results (16). Serum 209 
and pleural fluid NT-pro BNP levels are closely correlated (11), and therefore measurement 210 
of serum levels alone is thought to be sufficient (17). In our study the ability of serum NT-211 
pro BNP to establish a primary diagnosis of heart failure (sensitivity 76%, specificity 74%), or 212 
any contribution from heart failure in the aetiology of the pleural effusions (sensitivity 79%, 213 
specificity 88%) were significantly less impressive than those seen in previous studies. This 214 
difference is likely to be explained by the fact that our study recruited patients with 215 
undiagnosed unilateral effusions in whom the pre-test probability of heart failure was lower 216 
and there was diagnostic uncertainty at the time of enrolment. Additionally, the vast 217 
majority of previous studies examining NT-pro BNP have used pre-selected patient cohorts 218 
with strong evidence of CHF and clear-cut causes of effusions in control groups, excluding 219 
those with diagnostic uncertainty (15).  220 
This study would suggest that the previously stated assertion that “NT-pro BNP levels 221 
higher than 1500 pg/ml are virtually diagnostic of heart failure” (11) needs to be viewed 222 
with caution. Our finding of 13 patients with malignant pleural effusions and an NT-pro BNP 223 
≥ 1500 pg/ml highlights the potential danger of using NT-pro BNP in this way. Though this 224 
group may well have a degree of heart failure and respond to diuretics and the optimisation 225 
of cardiac treatment, it cannot be assumed that this group do not have an additional 226 
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pathological process requiring careful evaluation. In our view it is clear that the 227 
identification of one cause for a pleural effusion should not prevent more detailed 228 
diagnostic evaluation for alternative additional processes where this is thought to be 229 
clinically necessary. 230 
The median age in this study was 75 years and in view of the significant comorbidity of 231 
this age-group the incidence of multiple causes for pleural effusions may be higher than in 232 
other healthcare settings representing a younger population. Though patients’ diagnoses 233 
were established by two independent experienced clinicians, the work up of these patients 234 
may extend beyond that used in other clinical environments. As a result, the prevalence of 235 
multiple aetiology reported here may be higher than that seen in other populations with a 236 
less comprehensive work up. Additionally, as all patients were recruited from a single 237 
tertiary centre, the proportion of diagnoses may not be representative of those seen 238 
elsewhere. Specifically, the study may over-represent patients with mesothelioma, and low 239 
cytological diagnostic rates may reflect the patients referred to this centre following initial 240 
evaluation prior to referral. The validation of clinical diagnoses could have been made more 241 
robust with more thorough investigation, such as pleural biopsy in all patients, but this was 242 
not possible in this study, as in many patients such an approach would not be clinically 243 
justified. 244 
This study has not established whether clinical outcomes may be improved by the 245 
identification of a contributing processes, though clearly for some patients with a 246 
contributory cause such as pleural infection, malignancy or thromboembolic disease there 247 
would be a clear rationale for changing management. It is less clear whether the 248 
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identification and treatment of, for example CHF in a patient with pleural malignancy, will 249 
improve patient symptoms or clinical outcome. 250 
Serum NT-pro BNP levels have been shown to be independently associated with poor 251 
prognosis in patients with malignant pleural effusions (18). It has not been established 252 
whether this poorer prognosis is modified with the optimisation of cardiac treatment but 253 
this may be an area for investigation in future interventional studies. As well as potentially 254 
improving prognosis, the treatment of heart failure in patients with other aetiologies to 255 
their pleural effusion may attenuate the accumulation of pleural fluid, reduce the frequency 256 
of pleural aspirations or potentially improve the chances of successful pleurodesis. 257 
The possibility of multiple pathologies contributing to pleural effusions should prompt a 258 
robust diagnostic work up where indicated, which extends beyond the identification of one 259 
explanation for the effusion. NT-pro BNP levels may prove of value in the identification of 260 
patients with CHF as a contributing process leading to development of a symptomatic 261 
pleural effusion. Further interventional studies may help evaluate whether the identification 262 
and treatment of secondary aetiologies, particularly heart failure, may help improve patient 263 
outcomes in this comorbid patient population.  264 
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Figure Legends 315 
 316 
Figure 1: Study flow diagram 317 
A demonstration of the numbers of patients screened for and included in the study 318 
providing reasons for non-inclusion where necessary. 319 
 320 
Figure 2: Frequency of multiple aetiology by Primary diagnosis 321 
A bar chart illustrating the numbers of patients in each of the major diagnostic groups and 322 
the proportion of patients with a contributing secondary cause for their pleural effusion and 323 
whether that contributing cause was heart failure or another cause. 324 
Footnote: 325 
CHF – Congestive heart failure 326 
BAPE - Benign asbestos pleural effusion 327 
 328 
 329 
Figure 3: Light’s criteria classification by primary aetiology 330 
An illustration of the number of patients categorised as a transudate or exudate by Light’s 331 
criteria depending on the primary diagnostic category established after follow up. 332 
Footnote: 333 
CHF – Congestive heart failure 334 
BAPE - Benign asbestos pleural effusion 335 
  336 
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Table 1: Patient Demographics 338 
Patient Characteristics Result 
Age (years) – median (Interquartile range) 75 (67-79) 
Sex - no. (%)  
     Male 83 (66%) 
     Female 43 (34%) 
Side of Effusion - no. (%)  
     Left 48 (38%) 
     Right 78 (62%) 
Size of Effusion – no. (%)  
     Small 26 (21%) 
     Moderate 70 (56%) 
     Large 30 (24%) 
Inpatient or Outpatient – no. (%)  
     Outpatient 87 (69%) 
     Inpatient 39 (31%) 
World Health Organisation Performance Status  
     0 13 (12%) 
     1 53 (48%) 
     2 31 (28%) 
     3 11 (10%) 
     4 3 (3%) 
Primary Diagnosis  
Pleural Malignancy 58 (46%) 
Congestive Heart Failure 21 (17%) 
Pleural Infection 11 (9%) 
Benign Asbestos Pleural Effusion 11 (9%) 
Idiopathic pleuritis 8 (6%) 
Other (Haemothorax, Drug reaction or Trapped lung) 4 (3%) 
Pulmonary Embolism 4 (3%) 
Non-cardiac Transudate 3 (2%) 
Coronary Artery Bypass Graft 2 (2%) 
Rheumatoid Effusion 2 (2%) 
Undiagnosed 2 (2%) 
  339 
17 
 
Table 2: Pleural Fluid and CT Characteristics 340 
Variable Result (%) 
Light’s Criteria – no. (%)  
     Exudate 101 (80%) 
     Transudate 19 (15%) 
     Unavailable 6 (5%) 
Predominant cell type – no. (%)  
     Mesothelial cells 36 (29%) 
     Lymphocytes 34 (27%) 
     Eosinophils 8 (6%) 
     Neutrophils 7 (6%) 
     Other (Malignant cells, paucicellular, predominantly blood) 39 (31%) 
     Unavailable 2 (2%) 
CT Features  
     Benign appearances/Inflammatory 31 (24.6%) 
     Suspicious for malignancy 41 (32.5%) 
     Probable malignancy 17 (13.5%) 
     Definitely malignant 29 (23.0%) 
     Unavailable 8 (6.4%) 
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Table 3: Cytology and radiology results and rates of multiple aetiology in patients 343 
diagnosed with malignancy 344 
 Total (%) Diagnostic 
cytology (%) 
CT probable or 
definite 
malignancy (%) 
Multiple 
aetiology (%) 
Lung 17 (29%) 5 (29%) 17 (100%) 7 (41%) 
Mesothelioma 18 (31%) 2 (11%) 8 (44%) 1 (6%) 
Breast 5 (9%) 3 (60%) 5 (100%) 0 (0%) 
Gastrointestinal 4 (7%) 3 (75%) 3 (75%) 2 (50%) 
Renal 4 (7%) 0 (0%) 4 (100%) 0 (0%) 
Haematological 2 (3%)  1 (50%) 0 (0%) 1 (50%) 
Ovarian 2 (3%) 2 (100%) 1 (50%) 0 (0%) 
Other 6 (10%) 1 (17%) 3 (50%) 1 (17%) 
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Figure 1 347 
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Figure 3 374 
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